KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Assets (2016 - 2025)

Astrazeneca has reported Non-Current Assets over the past 11 years, most recently at $85.4 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $85.4 billion for Q4 2025, up 21.47% from a year ago — trailing twelve months through Dec 2025 was $85.4 billion (up 21.47% YoY), and the annual figure for FY2025 was $85.4 billion, up 21.47%.
  • Non-Current Assets for Q4 2025 was $85.4 billion at Astrazeneca, up from $70.3 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for AZN hit a ceiling of $85.4 billion in Q4 2025 and a floor of $68.9 billion in Q4 2022.
  • Median Non-Current Assets over the past 5 years was $70.3 billion (2024), compared with a mean of $73.3 billion.
  • Biggest five-year swings in Non-Current Assets: soared 67.54% in 2021 and later dropped 5.68% in 2022.
  • Astrazeneca's Non-Current Assets stood at $73.0 billion in 2021, then decreased by 5.68% to $68.9 billion in 2022, then rose by 0.15% to $69.0 billion in 2023, then increased by 1.88% to $70.3 billion in 2024, then increased by 21.47% to $85.4 billion in 2025.
  • The last three reported values for Non-Current Assets were $85.4 billion (Q4 2025), $70.3 billion (Q4 2024), and $69.0 billion (Q4 2023) per Business Quant data.